Antibody-Drug Conjugates

Antibody-Drug Conjugates (ADCs) are an important therapeutic modality, combining the antigen specificity of monoclonal antibodies with the cytotoxic activity of small-molecule payloads. Throughout ADC development, researchers face challenges in target validation, conjugation strategy optimization, internalization analysis, and bioanalytical characterization. ACROBiosystems provides integrated ADC research solutions spanning discovery through preclinical development, including target proteins, ADC conjugation kits, internalization detection tools, Fc receptor research tools, and ADC pharmacokinetic (PK) analysis solutions, including anti-payload antibodies and payload-specific ADC quantification ELISA kits. Our validated reagents support ADC research across key development stages.